Loading…
Travere Therapeutics, Inc. is projected to rise to $78.67 by 2027, a +65% move from its current price of $47.76. TVTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $46.47 | $47.79 | $49.15 | +0.06% |
| May 30 | $45.96 | $47.82 | $49.76 | +0.12% |
| May 31 | $45.58 | $47.85 | $50.23 | +0.18% |
| Jun 1 | $45.26 | $47.88 | $50.64 | +0.24% |
| Jun 2 | $44.99 | $47.90 | $51.01 | +0.30% |
| Jun 3 | $44.75 | $47.93 | $51.35 | +0.36% |
| Jun 4 | $44.53 | $47.96 | $51.66 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $44.53 | $47.96 | $51.66 | +0.42% |
| Week 2 | $43.36 | $48.17 | $53.50 | +0.85% |
| Week 3 | $42.53 | $48.37 | $55.01 | +1.28% |
| Week 4 | $41.87 | $48.58 | $56.36 | +1.71% |
| Week 5 | $41.32 | $48.78 | $57.60 | +2.14% |
| Week 6 | $40.84 | $48.99 | $58.77 | +2.58% |
| Week 7 | $40.42 | $49.20 | $59.89 | +3.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.
Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
TVTX trades at $47.76 with a market cap of $4.44B. It is ranked 1420 in market capitalization among listed companies.
Forecasts show bullish sentiment across the horizon, with the average price rising from $47.76 in 2026 to $132.30 by 2030 and to $936.75 by 2050. Notable milestones include 2027 avg $78.67 with ROI 64.7 and 2028 avg $101.21 with ROI 111.9, underscoring a multiyear upside path.
A major floor 43.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.5% above — clearing it would confirm fresh momentum.
Key TVTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.94 | Buy | $45.28 | Buy |
| MA 10 | $44.11 | Buy | $44.43 | Buy |
| MA 20 | $43.68 | Buy | $43.11 | Buy |
| MA 50 | $37.42 | Buy | $39.21 | Buy |
| MA 100 | $33.91 | Buy | $35.74 | Buy |
| MA 200 | $31.14 | Buy | $31.51 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.87 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 232.71 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | 12.11 | Buy |
| Bollinger %B (20,2) | 1.17 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 3.47 | Buy |
| Ultimate (7,14,28) | 75.28 | Sell |
| Momentum (10) | 4.92 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 45.83 | Buy |
| ADX (14) | 27.00 | Buy |
| ATR (14) | 1.10 | Info |
The 30-day technical picture is bullish.
RSI14 is 70, indicating strong momentum. The 50-day simple moving average sits at $37.42 and the 200-day moving average at $31.14, outlining an uptrend. Support is at $38.78 and resistance at $47.76, with the 30-day trading range between $39.69 and $57.47.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.79 | $47.76 | $72.90 | 0% | Neutral | |
| $62.22 | $78.67 | $105.48 | +65% | Bullish | |
| $77.84 | $101.21 | $140.75 | +112% | Bullish | |
| $83.40 | $111.01 | $158.91 | +132% | Bullish | |
| $97.34 | $132.30 | $194.06 | +177% | Bullish | |
| $105.54 | $146.20 | $219.09 | +206% | Bullish | |
| $111.42 | $157.12 | $240.01 | +229% | Bullish | |
| $150.89 | $216.35 | $336.31 | +353% | Bullish | |
| $177.61 | $258.74 | $408.71 | +442% | Bullish | |
| $185.09 | $273.78 | $438.97 | +473% | Bullish | |
| $301.98 | $478.75 | $817.13 | +902% | Bullish | |
| $524.08 | $936.75 | $1,751.53 | +18.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.79 | $47.76 | $55.99 | +0.00% |
| June 2026 | $41.33 | $48.57 | $58.45 | +1.70% |
| July 2026 | $42.58 | $50.47 | $61.59 | +3.91% |
| August 2026 | $42.36 | $50.55 | $62.34 | +0.15% |
| September 2026 | $42.86 | $51.44 | $63.99 | +1.77% |
| October 2026 | $45.56 | $54.95 | $68.90 | +6.83% |
| November 2026 | $47.20 | $57.19 | $72.19 | +4.07% |
| December 2026 | $47.14 | $57.38 | $72.90 | +0.33% |
Click any year to see its month-by-month TVTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TVTX is projected to trade between $26.79 and $72.90, averaging $47.76 — a potential gain of 0% from today's $47.76. A consolidation phase looks the most probable path here.
Travere Therapeutics, Inc.'s 2027 outlook centres on $78.67, within a $62.22 to $105.48 range. That is up +65% on the projected 2026 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2028, TVTX could reach as high as $140.75, with a base case around $101.21 and support toward $77.84 — roughly +112% from $47.76. Buyers look set to stay in control over this stretch.
Expect TVTX to range from $83.40 to $158.91 through 2029. The $111.01 average target implies a +132% move from current prices. That is up +10% on the projected 2028 average. Momentum favours further upside here.
The TVTX price prediction for 2030 points to an average of $132.30 (low $97.34, high $194.06) — a potential gain of +177% on today's $47.76. Buyers look set to stay in control over this stretch.
In 2031, TVTX is projected to trade between $105.54 and $219.09, averaging $146.20 — a potential gain of +206% from today's $47.76. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Travere Therapeutics, Inc.'s 2032 outlook centres on $157.12, within a $111.42 to $240.01 range. That is up +7% on the projected 2031 average. That marks a +229% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TVTX could reach as high as $336.31, with a base case around $216.35 and support toward $150.89 — roughly +353% from $47.76. Momentum favours further upside here.
Expect TVTX to range from $177.61 to $408.71 through 2034. The $258.74 average target implies a +442% move from current prices. That is up +20% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TVTX price prediction for 2035 points to an average of $273.78 (low $185.09, high $438.97) — a potential gain of +473% on today's $47.76. Momentum favours further upside here.
In 2040, TVTX is projected to trade between $301.98 and $817.13, averaging $478.75 — a potential gain of +902% from today's $47.76. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Travere Therapeutics, Inc.'s 2050 outlook centres on $936.75, within a $524.08 to $1,751.53 range. That is up +96% on the projected 2040 average. That marks a +18.6x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TVTX today (≈ 20.938023 TVTX) could be worth
$19,613.7
+$18,613.7 (+1861%) by 2050 · US Dollar
Based on the average projected TVTX price of $936.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVTXwould be worth at today's price.
$1,000 invested in TVTX on May 27, 2025 (≈ 65.189048 TVTX) would be worth
$3,113.43
+$2,113.43 (+211.3%) today · 3.11× · US Dollar
Based on a TVTX entry price of $15.34 vs. today's $47.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $43.49 | $1,098.18 | +9.8% |
| 1 month ago | $40.81 | $1,170.3 | +17.0% |
| 3 months ago | $29.72 | $1,607 | +60.7% |
| 6 months ago | $35.41 | $1,348.77 | +34.9% |
| 1 year ago | $15.34 | $3,113.43 | +211.3% |
| All time (5.0y) ago | $14.46 | $3,302.9 | +230.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVTX forecast.
Our base-case forecast reaches $96.00 around 2028.
Implied market cap at $96.00: $8.93B
Over the forecast horizon, the stock shows meaningful upside as averages rise across years. The 2026 average is $47.76 with ROI 0 and neutral sentiment. By 2027 the average is $78.67 with ROI 64.7 and bullish sentiment, followed by 2028 at $101.21 with ROI 111.9 and 2029 at $111.01 with ROI 132.4.
By 2030 the average price reaches $132.30 with ROI 177 and bullish sentiment, then 2031 at $146.20 with ROI 206.1 and 2032 at $157.12 with ROI 229. The 2033 forecast jumps to $216.35 with ROI 353 and 2034 to $258.74 with ROI 441.8, with 2035 at $273.78 and continuing bullish momentum.
Longer horizon targets show substantial gains: 2040 average $478.75 with ROI 902.4 and 2050 average $936.75 with ROI 1861.4, both with bullish sentiment. These are estimates and not guarantees, and actual results may vary based on numerous factors.
Tap a question to reveal the answer.
Average $132.30; min $97.34; max $194.06; ROI 177; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 onward, with averages rising toward $936.75 by 2050; these are estimates and not guarantees.
Yes. The forecast for 2027 shows a max of $105.48 and an average of $78.67, with sentiment BULLISH and ROI 64.7.
Low $39.69, high $57.47.
Travere Therapeutics, Inc. Community Discussion
0Share your Travere Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.